Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Afamelanotide: Treatment Comparison

Afamelanotide's clinical profile differs substantially from alternative photoprotection strategies. This table compares mechanism, duration, evidence base, and patient suitability. Afamelanotide (Scenesse) MC1R agonist triggers eumelanin synthesis independent

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Afamelanotide's clinical profile differs substantially from alternative photoprotection strategies. This table compares mechanism, duration, evidence base, and patient suitability.
  • Afamelanotide (Scenesse)
  • MC1R agonist triggers eumelanin synthesis independent of UV; subcutaneous PLGA implant releases 16mg over 60 days
  • 90–120 days per implant (melanin persists beyond peptide clearance)
  • Phase III RCT in EPP (N=94): +69.4h pain-free sun exposure vs +40.8h placebo over 180 days (p<0.001)
  • EPP patients seeking extended outdoor tolerance; requires specialist administration
  • Only FDA/EMA-approved pharmacological photoprotection for EPP; implant format ensures adherence but limits dose flexibility
  • Topical Sunscreen (SPF 50+, broad-spectrum)
  • Physical/chemical UV filters block or absorb UVA/UVB before reaching epidermis
  • 2–4 hours per application (requires reapplication)
  • Extensive observational data linking regular use to reduced photoaging and skin cancer; no RCTs in EPP specifically
  • All photosensitive patients; first-line for PMLE, solar urticaria, XP
  • Essential adjunct even with afamelanotide; does not address visible light phototoxicity (400–700nm) relevant in EPP
  • Beta-Carotene (Oral, 150–300mg/day)
  • Antioxidant quenches singlet oxygen; investigated in EPP before afamelanotide approval
  • Requires 8–12 weeks to reach steady-state; effect lasts only during supplementation
  • Mixed evidence; older trials suggested mild benefit in EPP, but Cochrane review (2012) found insufficient quality data
  • EPP patients unable to access afamelanotide; historical standard of care
  • No longer recommended as monotherapy; effect size far smaller than afamelanotide; skin discoloration (carotenodermia) common
  • Narrow-Band UVB Phototherapy (311nm)
  • Controlled UV exposure induces gradual melanin production and epidermal thickening
  • Requires 3x/week sessions for 6–8 weeks; effect fades over 3–6 months
  • Strong evidence for vitiligo repigmentation; limited data in EPP (may worsen phototoxicity)
  • Vitiligo, PMLE (pre-seasonal hardening); contraindicated in EPP and XP
  • Induces reactive photoprotection (UV damage precedes melanin); mechanism opposite to afamelanotide's proactive approach
  • Behavioral Avoidance + Photoprotective Clothing
  • Physical barrier prevents photon exposure entirely
  • Continuous during use
  • Observational data only; reduces phototoxic episodes in EPP but profoundly restricts quality of life
  • All photosensitive patients; mandatory baseline for EPP
  • Non-negotiable foundation; afamelanotide supplements but does not replace physical photoprotection